A study published in the journal The Lancet has shown that the weight loss drug Liraglutide could help cut your risk of diabetes by an astonishing 80%, when combined with diet and exercise.
What research was undertaken?
For this study 2,254 adults with prediabetes from 27 different countries around the world were split into 2 groups.
The first were given Liraglutide, which was injected under the skin daily for 160 weeks. Those in the second group were given a placebo.
Both groups were placed on a reduced calorie diet, and were recommended to get regular exercise too.
What were the results of the study?
At the conclusion of the study it was revealed that those who had been injected with the Liraglutide had significantly reduced their risk of developing type 2 diabetes.
The study showed that 60% of those with borderline diabetes had seen their condition reverse, with their blood sugar levels returning to a healthy level.
It was also discovered that those in this group had lost 7% of their bodyweight, compared to just a 2% drop in the placebo group.
John Wilding, Professor at the University of Liverpool had this to say about the findings:
“Liraglutide 3.0 mg can provide us with a new therapeutic approach for patients with obesity and prediabetes.”
How does Liraglutide work?
Liraglutide is a weight loss drug that is designed to promote weight loss by activating the areas of your brain that control your appetite.
By ensuring you feel fuller sooner during meals you will consume less food, which will ultimately result in weight being lost.
Apart from its weight loss benefits, this new study on its ability to reduce the risk of diabetes is extremely promising.